Five-and ten-year survival ratcs for Stage 11 mammary carcinoma Survivalrates Author Five years Ten years Bucholtz(1928) 45-2% 24-1% Pfahler(1931) 58% 32% Urban(1956) 39 4% 21-2% Jackson &Jackson (1958) 58 1%
28-4% Porritt(1964) 42-5% 31% Bruce et al.(1968) 50% 38 % negative. However, in the majority of series there is a marked fall in the ten-year survival rate compared to the five-year survival rate, following treatment for 'early' mammary cancer (Table 1) and this emphasizes the unreliability of the fiveyear 'cure' rate. Although this patient responded to the bilateral oophorectomy she did not obtain an objective remission of her disease following the pituitary ablation until cyclophosphamide was added into the regime. Since then her liver, which was enlarged and irregular, has diminished in size so that it is no longer palpable. She also feels extremely well and is able to perform a full day's work.
The treatment of advanced mammary cancer has been based on hormonal or endocrine ablative surgery (British Medical Journal 1969) , but some workers now wonder whether chemotherapeutic agents have a role to play. At Hammersmith Hospital a controlled, paired, randomized trial is currently being carried out to assess the value of cyclophosphamide following pituitary ablation in the treatment of this disease.
The response in our patient to hormonal and chemotherapy is extremely unusual as she had such severe, histologically proved, hepatic involvement; but it indicates how important it is to treat these patients even if they are very ill and despite severe hepatic involvement, as results like this make it very well worth while.
Mr Burn commented that the patient had a temporary but good response to oophorectomy and, therefore, a further period of remission was to be expected after pituitary ablation. There was no change in the hepatomegaly, however, until cyclophosphamide therapy was started. After fifteen months' treatment the liver now had returned to normal size and the patient was very well.
Cytotoxic chemotherapy had a palliative role in advanced mammary cancer. Because of the relative success of endocrine methods it should in general be reserved as the final form of treatment. Useful response could be expected in about 25 % of patients, especially those with lesions of the skin and soft tissues. Response of hepatic metastases to systemic cytotoxic therapy was unusual.
Undoubtedly the two most popular cytotoxic agents in the treatment of advanced adenocarcinoma of the breast were 5-fluorouracil and cyclophosphamide; 5-fluorouracil had the disadvantage of not being available as an oral preparation and, therefore, cyclophosphamide was preferred for nmaintenance therapy.
Lung Changes in Sjogren's Syndrome
A J Karlish MD MRCP (Royal Berkshire Hospital, Reading) Mrs E P, aged 61 In 1965 complained of dryness of the eyes and mouth with transient polyarthralgia. Examination revealed keratoconjunctivitis sicca and xerostomia with parotid and submandibular gland enlargement. Parotid biopsy showed lymphocytic and plasma cell infiltration with acinar atrophy as well as the 'epithelial islands' described in Sjogren's syndrome. The chest X-ray was normal. There was no evidence of rheumatoid arthritis.
When seen again in April 1968 she had a cough with some sputum as well as dryness of the eyes and mouth. The parotid glands were grossly enlarged, numerous rales were heard at both bases and an X-ray of the chest showed extensive fibrotic changes in both lower zones.
Pulmonary Junction tests (Dr R Marshall) showed considerable impairment of diffusing capacity and compliance: Po2 was 57 mmHg and arterial oxygen saturation 77 % at rest. Lung biopsy (Professor Lynne Reid): Dense interstitial fibrosis with loss of alveolar and small airway structures. Where the alveolar pattern can be recognized the walls are thickened. There is lymphocytic infiltration resembling that seen in the parotid. The van Giesen stain shows increase in collagen and round collections of brightly staining hyaline-like material, sometimes in blood vessel walls, sometimes in what appear to be alveolar spaces. Bronchoscopy showed a dry and shiny mucosa with only a few submucous glands in the bronchial biopsy sections. Serology: DAT 1/16, latex + +. Lung antibodies present at low titre (Dr M Turner-Warwick). Antinuclear factor, LE cells and thyroid antibodies absent. Progress: Prednisolone treatment caused considerable regression of parotid enlargement but no change in the dryness of the eyes or mouth. There were no more rales at the bases and X-rays showed moderate clearing in both lower zones. Pulmonary function tests showed improvement in diffusing capacity and compliance with Po2 and arterial oxygen saturation back to near normal.
Comment
There are few histological reports of lung lesions in Sjogren's syndrome. We found only 3 autopsy cases (Ellman et al. 1951 , Cardell & Gurling 1954 , Bucher & Reid 1959 ) and 2 lung biopsies (Bates & Christie 1964 , Bloch et al. 1965 . The amorphous hyaline-like material seen in our lung biopsy was also noted by Bucher & Reid and Bloch et al. All 3 cases are examples of the 'sicca' syndrome. Pulmonary function tests in the case reported by Bates & Christie were consistent with the histological findings of interstitial pulmonary fibrosis. In the cases reported by Ellman et al. and Cardell & Gurling the lung lesion was thought to be lipid pneumonia.
